Four methods compared for measuring des-carboxy-prothrombin (PIVKA-II).

Widdershoven, J.; Munster, P. J. J. Van; Abreu, RA De; Bosman, H.; Lith, T v; Meyel, M van der Putten-van; Motohara, Kunihiko; Matsuda, Ichiro

doi:10.1093/clinchem/33.11.2074

Cited by 55 publications

(23 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously reported [9,15] the ELISA and Echis assays were highly correlated (data not shown). The plasma prothrombin data presented below was obtained using the Echis assay to measure total prothrombin.…”

Section: Discussionsupporting

confidence: 86%

See 1 more Smart Citation

Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase

et al. 1998

View full text Add to dashboard Cite

Control of warfarin anticoagulation during the initial phase of therapy is difficult and empirically based. Plasma and urine samples were obtained from normal controls, patients under stable anticoagulation, and patients in the initial phase of anticoagulation. Total plasma prothrombin, des-carboxy (non-adsorbable with barium chloride) prothrom-bin, and native (total minus non-adsorbable) prothrombin were quantitated using Echis carinatus venom activation. Functional plasma factor VII (VII) was measured using a one-stage clotting assay. Total and des-carboxy urine prothrombin F1 (F1) were measured by ELISA. All urine F1 in normals and both anticoagulated groups was adsorbed by barium chloride. Plasma des-carboxy prothrombin concentration was similar for the two anticoagulated groups and did not correlate with 1/INR. Native prothrombin correlated with 1/INR in both the stable (r = 0.76) and initial phase (r = 0.74) groups. For any given INR, the subjects on stable anticoagulation had lower native prothrombin concentrations than the initial phase patients. Functional factor VII concentration also correlated significantly with 1/INR in both the stable (r = 0.64) and initial phase (r = 0.76) patients. Unlike native prothrombin, VII concentrations did not vary between the two cohorts for any given INR. Previous studies indicate that native prothrombin is a superior predictor of both hemorrhagic and thromboembolic complications during warfarin therapy. Our findings indicate that VII, and not prothrombin, may be the predominant factor monitored by the INR. This further supports the need to reevaluate the usefulness of the INR in the monitoring of warfarin therapy during the initial phase. Am.

show abstract

Section: Discussionsupporting

confidence: 86%

“…There are various methods available for the measurement of native prothrombin and its des-carboxy or undercarboxylated derivatives [5,[14][15][16]. By varying the target region, immunologic methods can be sensitive to the native prothrombin [17], the des-carboxylated derivative [18], or both.…”

Section: Introductionmentioning

confidence: 99%

Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase

et al. 1998

View full text Add to dashboard Cite

show abstract

“…In another study, Sokol et al (1 5 ) did not detect PIVKA-I1 during the first year of life in any of 21 C F infants. However, their method of measuring PIVKA-I1 was less sensitive than ours (6). Also, all infants had received vitamin K prophylaxis after birth.…”

Section: Discussionmentioning

confidence: 62%

Vitamin K status in cystic fibrosis

Cornelissen¹,

Lieburg²,

Motohara

et al. 1992

Acta Paediatrica

Self Cite

View full text Add to dashboard Cite

Appearance of PIVKA-II (protein induced by vitamin K absence-II) in serum is a biochemical sign of insufficient vitamin K-dependent carboxylation of prothrombin. Plasma concentrations of PIVKA-II and vitamin K1 were determined in 24 children with cystic fibrosis. Eight were supplemented with vitamin K1. The purpose of the study was to determine the occurrence of vitamin K deficiency in cystic fibrosis and to evaluate the effect of vitamin K supplementation. PIVKA-II was detectable in only one unsupplemented child. In this patient, the concentration of vitamin K1 was below the limit of detection of 60 ng/l. Vitamin K1 levels in the other unsupplemented children were normal (mean 476 ng/l = 1 mmol/l). The supplemented patients showed extremely high levels of vitamin K1 (mean 22445 ng/l = 50 nmol/l). In conclusion, vitamin K deficiency occurs infrequently in cystic fibrosis. Checking the coagulation system is advised, but routine vitamin K supplementation is not recommended. If additional vitamin K is needed, the starting dose should not exceed 1 mg daily.

show abstract

“…Unsupplemented breast-fed infants daily ingest less than 1 pg of vitamin K I (14), while the required daily intake (RDI) amounts to 5 pg (16). Accordingly, in formula-fed infants, PIVKA-IT is not detectable (8) and haemorrhagic disease is almost confined to breast-fed infants (2). Prothrombin times were reported to be longer in threemonth-old breast-fed infants than in formula-fed infants, despite vitamin K prophylaxis at birth (14).…”

Section: Discussionmentioning

confidence: 99%

Prevention of vitamin K deficiency in infancy by weekly administration of vitamin K

Cornelissen¹,

Kollée²,

Abreu³

et al. 1993

Acta Paediatrica

View full text Add to dashboard Cite

Vitamin K prophylaxis has been developed to prevent classic haemorrhagic disease of the newborn. Single vitamin K administration after birth has been reported to fail, resulting in late haemorrhagic disease of the newborn. The preventive effect of oral administration of vitamin K1 1 mg, repeated weekly during the first three months of life, was studied in 48 healthy breast-fed infants, by determination of thrombotest, PIVKA-II and vitamin K1 concentrations at the age of 4, 8 and 12 weeks. All infants showed normal thrombotest values and PIVKA-II was not detectable. Vitamin K1 concentrations were negatively correlated with the number of days elapsed since the most recent vitamin K administration. Six to seven days after the latest application, mean levels were 1223, 927 and 748 pg/ml at ages 4, 8 and 12 weeks, respectively. In conclusion, weekly administration of vitamin K1 1 mg offers complete protection against vitamin K deficiency and does not result in an accumulation of vitamin K1 in the blood.

show abstract

Four methods compared for measuring des-carboxy-prothrombin (PIVKA-II).

Cited by 55 publications

References 11 publications

Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase

Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase

Vitamin K status in cystic fibrosis

Prevention of vitamin K deficiency in infancy by weekly administration of vitamin K

Contact Info

Product

Resources

About